The CIS-treated group showed a significant (p ≤ 0.0001) increase in LDHA activity in serum and liver tissue, and showed no significant change in LDHA activity in EAC cells as compared to the EQ + CIS-treated group (Figure 3). This evidence concerns the gene LDHA and in situ carcinoma.